The most common genotype associated with severe a-1-antitrypsin deficiency (AATD) is the Z homozygote. The Z variant (Glu342Lys) of a-1-antitrypsin (AAT) undergoes a conformational change and is retained within the endoplasmic reticulum (ER) of hepatocytes leading to the formation of ordered polymeric chains and inclusion bodies. Accumulation of mutated protein predisposes to cirrhosis whilst plasma AAT deficiency leads to emphysema. Increased risk of liver and lung disease has also been reported in heterozygous subjects who carry Z in association with the milder S allele (Glu264Val) or even with wild-type M. However, it is unknown whether Z AAT can co-polymerize with other AAT variants in vivo. We co-expressed two AAT variants, each modified by a different tag, in cell models that replicate AAT deficiency. We used pull-down assays to investigate interactions between co-expressed variants and showed that Z AAT forms heteropolymers with S and with the rare Mmalton (Phe52del) and Mwurzburg (Pro369Ser) mutants, and to a lesser extent with the wild-type protein. Heteropolymers were recognized by the 2C1 mAb that binds to Z polymers in vivo. There was increased intracellular accumulation of AAT variants when co-expressed with Z AAT, suggesting a dominant negative effect of the Z allele. The molecular interactions between S and Z AAT were confirmed by confocal microscopy showing their colocalization within dilated ER cisternae and by positivity in Proximity Ligation Assays. These results provide the first evidence of intracellular co-polymerization of AAT mutants and contribute to understanding the risk of liver disease in SZ and MZ heterozygotes.
Introduction
Alpha-1-antitrypsin deficiency (AATD) is a genetic disorder caused by mutations in the SERPINA1 gene encoding for a-1-antitrypsin (AAT) (OMIM #613490 and #107400), which lead to reduced levels of the protein in the circulation. AAT is the most important inhibitor of serine proteases and lack of this protein exposes tissues to uncontrolled proteolytic damage, particularly the lungs. As a result, individuals with AATD have an increased risk of early onset emphysema and chronic obstructive pulmonary disease (COPD) (1) . AATD is also associated with liver disease as a result of deposition of polymers of mutant AAT within the endoplasmic reticulum (ER) of hepatocytes, where AAT is chiefly produced (2) .
The most frequent and polymerogenic SERPINA1 variant associated with severe AATD is named Z (Glu342Lys) (3) . Z AAT homozygotes have a plasma AAT level that is 10-20% of normal and an increased risk of pulmonary disease (1, 4) . Most ZZ patients also develop liver disease, which can manifest as severe hepatitis in the neonatal period (4, 5) , cirrhosis and hepatocellular carcinoma (6) . Several models have been proposed to explain the mechanism by which the Z mutation causes the formation of ordered polymeric chains in the ER (1), but it is unclear how these polymers deposit in inclusion bodies (IB) and how this process leads to cytotoxicity and liver disease. AATD is a recessive disorder, as heterozygous MZ subjects, who carry Z with the wild-type M AAT allele, are generally healthy. However, large epidemiological studies have reported an increased risk of COPD in individuals with the MZ genotype (4, 7, 8) . The Z variant in heterozygotes may be a co-factor in the progression of chronic liver disease associated with alcohol abuse, fatty liver, viral infection and other environmental or genetic factors (4, 7, 9) .
The S variant (Glu264Val) is a highly prevalent AAT allele in Southern Europe (3) and is characterised by AAT plasma concentrations of 60% of the wild type allele, sufficient to protect SS homozygotes from lung disease. Moreover, the misfolding defect of the S AAT leads the variant to intracellular degradation rather than accumulation in the ER (10) (11) (12) , ensuring SS homozygotes not to develop liver disease (4, 13) . However, when the Z and S alleles are inherited together then plasma levels are 25-35% of normal and there is a risk of both liver and lung disease (4, 13, 14) .
Several rare pathological AAT variants have been reported in association with the Z allele (13, 15) . Most of these variants have been described in single cases or with limited genotypephenotype correlation. Nonetheless, there is evidence that some rare mutants accumulate in hepatocytes as polymers, such as Mmalton (Mal) (Phe52del), Siiyama (Ser53Phe), King's (His334Asp) and to a lesser extent Mwurzburg (W) (Pro369Ser) and Pbrescia (Gly225Arg) (16) (17) (18) (19) (20) .
Although the compound heterozygous condition found in SZ AAT subjects or in rare/Z AAT genotypes is clinically important, the co-expression of two variants has never been investigated in a cellular setting. In this study, we have developed a strategy to reproduce AAT compound heterozygosity in cells and investigated the formation of heteropolymers between Z and other variants of AAT.
Results

Development of a cellular model to study heterozygosity in AATD
To study the molecular interactions between AAT variants in cells, we established an experimental model in which we coexpressed two AAT variants, respectively modified by the influenza hemagglutinin (HA) tag or the myc tag at the C-terminus of the protein. To test whether addition of tags affected the overall behaviour of the variants, we expressed in HEK293T cells either the untagged or the tagged variants and compared them by assessing their secretion efficiency as well as their ability to form polymers (Fig. 1) . After transfection, HEK293T cells were grown in the absence of serum for 24 h. Cell media were then collected, and the cells lysed in a buffer containing the mild NP40 detergent, followed by centrifugation, to separate the soluble cytoplasmic material from the NP40-insoluble fraction containing nuclei and large protein aggregates. The different fractions were analysed by SDS-PAGE and immunoblot with anti-AAT antibodies (Fig. 1A) . Even when modified by tags, the wild-type M and the AAT mutants showed the expected profile: M was secreted efficiently, showed low levels in the NP40-soluble fraction, and was undetectable in the insoluble material; in comparison Z, S, Mal and W mutants were deficient in secretion and accumulated in both the NP40-soluble and -insoluble intracellular fractions. In our expression conditions, after loading equivalent amounts of the two intracellular fractions, the percentage of NP40-insoluble S and Z were 15 and 30%, respectively (Fig. 1B) . AAT concentrations in cell media were quantified by ELISA (Fig. 1C) . Compared to the level of M, set as 100%, both Z and Mal were severely deficient (respectively, 15 and 10%), while S and W showed milder secretory defects (respectively, 40 and 45%). The extracellular levels of the tagged variants, expressed as percentages of the M myc control, behaved similarly to the corresponding unmodified variants.
As demonstrated previously (19, 21, 22) , polymers accumulate within the cells but can also be detected in the cell media with a polymer/monomer ratio that reflects the intrinsic tendency of each mutant to polymerise. We therefore analysed the cell supernatants of transfected HEK293T by non-denaturing PAGE and immunoblot analysis (Fig. 1D) . While the normal M AAT and its tagged counterparts are exclusively in the monomeric form, the mutants show a typical monomer to polymer proportion, independent of the presence of tags. Taken together these data rule out major effects of C-terminal tag addition on AAT variant handling by cells.
Z forms mixed polymers with S and rarer AAT variants
To investigate the interactions between Z and other AAT variants in cells, Z HA was co-transfected in HEK293T cells with the myctagged versions of M, Z, S, Mal or W. As a control, M myc , Z HA , Z myc and S myc were transfected alone. In order to evaluate the expression levels of each variant and verify the specificity of anti-tag antibodies, the NP40-soluble cell extracts were analysed by immunoblot with antibodies against total AAT, myc or HA tag ( Fig. 2A) . To investigate the formation of heterocomplexes between Z HA and the co-expressed myc-tagged variants, the same samples were subjected to a pull-down assay with anti-HA antibodies (Fig. 2B) . The immunoprecipitated material was first probed with anti-AAT antibodies showing comparable levels of immunoprecipitation (IP) except for cells expressing Z myc only (Fig. 2B, upper panel) . The same membrane was stripped and probed by anti-myc 9E10 mAb in order to detect AAT variants pulled-down along with Z HA (Fig. 2B, lower panel) . As expected, Z myc was efficiently co-immunoprecipitated from cells expressing both Z HA and Z myc . S myc and the other mutants were similarly coimmunoprecipitated, showing the formation of heterocomplexes with Z HA . Interestingly, also a small fraction of the wild-type M was found in association with Z HA .
To clarify whether the co-IP shown in panel B was due to formation of mixed polymers, we took advantage of the 2C1 mAb, a conformational antibody that specifically recognizes AAT polymers in liver biopsies from ZZ patients (18) and in the plasma (21) . We used the 2C1 mAb to set up a novel biochemical assay to immunopurify polymers from the cell extracts. The efficiency of IP with 2C1 mAb was first tested on cells expressing Z HA , showing that, in our experimental conditions, about 10% of Z AAT present in the NP40-soluble cell extract was precipitated by 2C1 and that the precipitated polymers could be eluted from beads by mild acid treatment (Fig. 2C ).
Polymers were immunopurified with 2C1 mAb from HEK293T cells co-transfected with Z HA Z myc , S myc Z HA and M myc Z HA , then re-immunoprecitated with anti-HA antibodies and analysed by SDS-PAGE and immunoblot. Membranes were probed with both anti-HA and anti-myc antibodies (Fig. 2D) , showing that, when co-expressed, S myc and Z HA are associated in 2C1-positive polymers. In order to exclude that acidic elution may artificially induce association of S and Z AAT, a control IP was performed on a sample obtained by mixing the NP40-soluble extracts of cells expressing either S myc or Z HA , treated with acid (Z HA þS myc ). Similar results were obtained coexpressing S myc and Z HA in Hepa cells (data not shown).
In summary, our results demonstrate that the S variant, and to a lesser extent the wild-type M, form 2C1-positive heteropolymers when co-expressed with Z AAT.
Co-polymerization with Z increases intracellular accumulation of S and M AAT
Heterocomplex formation with Z AAT would be expected to affect the intracellular accumulation of the co-expressed AAT variants. We therefore analysed the intracellular decay of M myc , S myc and Z myc expressed alone or in the presence of Z HA . Transfected HeLa cells were treated with cycloheximide (CHX, 50 mg/ml) in a time course of 8 h. The immunoblots of intracellular AAT at the different time points and their densitometric analysis ( Fig. 3) showed that M myc quickly cleared from the cell as a result of rapid secretion, while a large proportion of Z myc persisted over the 8 h of CHX treatment. S myc showed an intermediate behaviour, in agreement with previously published data (12) . When co-expressed with Z HA , both M myc and S myc exhibited a slower decay. Under the same co-expression conditions, we did not observe major effects of Z on the secretion of either S or M AAT (Supplementary Material, Fig. S1 ). Comparable results were obtained in the Hepa 1-6 cellular model (data not shown).
In summary, co-expression with Z AAT modifies the behaviour of S and M AAT, favouring their intracellular accumulation.
The S and Z variants co-localize in dilated ER cisternae
In order to study their localization by immunofluorescence, tagged M, S and Z variants were expressed alone or in combinations in HeLa cells for 24 h. M myc , S myc and Z myc cells were fixed and stained with anti-myc mAb in combination with antibodies to either GM130, a cis-Golgi marker, or to the ER marker calreticulin (CRT) (Fig. 4) . Co-localization was analysed by determining Mander's coefficients as represented by histograms (Fig. 4 , right panels). As expected for an efficiently secreted protein, M myc colocalizes with GM130. Z HA and S myc show weaker co-staining with this marker (Fig. 4A) . In contrast, these two variants show significant co-localization with CRT, confirming their accumulation in the ER. Interestingly, Z HA is enriched in CRT-positive dilated cisternae around the nuclei and is relatively less abundant in the peripheral ER which preserves its reticular morphology (23, 24) .
To mimic the heterozygous condition found in AATD patients, we co-expressed Z HA with the myc-tagged versions of M, S or Z AAT and stained the cells with anti-HA and anti-myc antibodies ( Fig. 4E and F) . As positive control of co-localization, we observed a complete staining overlap in the cells coexpressing Z myc and Z HA . A significant co-staining was also observed in S myc Z HA cells. S myc is both co-localized with Z HA in IB and distributed as single staining in the peripheral ER. Interestingly, also M myc and Z HA displayed a remarkable overlap within dilated vesicular structures, although part of M AAT segregates from Z in a peri-nuclear area that likely represents the Golgi apparatus. Similar results were obtained in COS-7 cells (data not shown).
Taken together, our results show, within the resolution limits of this confocal technique, co-localization of S and M AAT within Z AAT IB. analysed by non-reducing 7.5% w/v acrylamide native-PAGE and immunoblot with anti-AAT pAb to evaluate the polymer/monomer ratio.
The Z and S AAT variants are in close proximity in the cells
To further investigate the co-localization of AAT variants within the ER we used the Proximity Ligation Assay (PLA), a technique developed to demonstrate proximity of two epitopes within 4-40 nm (25) . HeLa cells expressing M myc M HA , S myc M HA , M myc Z HA , S myc Z HA or Z myc Z HA were treated with anti-tag antibodies and processed with the PLA procedure, to mark adjacent HA and myc epitopes by fluorescence spots.
Micrographs in Figure 5A demonstrate that M myc M HA and S myc M HA co-expressing cells were negative in the PLA, while fluorescent spots were evident in M myc Z HA , S myc Z HA and Z myc Z HA cells. Positive cells did not show substantial differences in spot distribution among samples. The efficiency of cotransfection was determined in parallel by conventional immunofluorescence with antibodies to the HA and myc tags and shown to be similar in all different samples (Supplementary Material, Fig. S2 and Table S1 ).
We further processed the PLA acquisitions with the software Blobfinder, to determine the red fluorescence intensity per cell, which is represented in a scatter plot (Fig. 5B) . Both M myc M HA and S myc M HA showed basal values, while cells expressing M myc Z HA , S myc Z HA and Z myc Z HA combinations displayed increasing intensities of PLA signal, although with high internal variability. Assuming the average of M myc M HA cells as background, we determined the number of PLA positive cells, regardless of their intensity (Fig. 5C ). This analysis confirmed that S myc Z HA and Z myc Z HA behave similarly, demonstrating that the two coexpressed variants are in close proximity. Conversely, M myc Z HA positive cells were less abundant and less intense (Fig. 5B  and C) . Similar results were obtained in the COS-7 cellular model (data not shown).
Taken together, the PLA data presented here, and the pulldown assays showed in Figure 2 demonstrate that S myc Z HA , and to a lesser extent M myc Z HA , physically interact within the cell.
Discussion
Liver disease is common in Z AAT homozygotes (4-6) but is also seen in individuals with SZ and rare/Z genotypes (1,4,9,26). Moreover, MZ AAT heterozygotes are over represented on liver transplant waiting lists (27, 28) , suggesting that the single Z allele is sufficient to cause liver disease or that it is a co-factor with other conditions such as alcohol abuse, fatty liver or viral hepatitis. The principal cause of chronic liver disease in AATD is the accumulation of AAT polymers within the ER of hepatocytes (2). This is clearly the case for Z AAT homozygotes, but it is unknown whether Z forms heteropolymers with other polymerogenic mutants within the hepatocyte and indeed, whether it can form polymers with the wild type M AAT. The only work to date has shown that Z can form heteropolymers with S, but not M AAT, in biochemical assays (29) . In this report, we have studied the molecular interactions between Z and other AAT mutants in cells to reflect the cellular handling of AAT in individuals who are heterozygous for the Z allele. In particular, we have investigated whether Z AAT can heteropolymerize with other variants and thereby exert a dominant negative effect on the intracellular retention of milder variants, such as the common S mutant or the wild-type M AAT.
Our co-expression experiments show for the first time that molecular interactions and co-polymerization involving two AAT variants can occur in cells. We demonstrated, by pulldown experiments, the formation of intracellular complexes between Z and Mal (Phe52del) AAT. This is not surprising as both Z and Mal rapidly form polymers in vitro and in cell models of disease (12, 30) . Z AAT also formed heteropolymers with the less polymerogenic S (Glu264Val) and W (Pro369Ser) variants. The SZ AAT heteropolymers were investigated in more detail and shown to be recognized by the polymer-specific 2C1 monoclonal antibody. This implies that SZ heteropolymers share an epitope with pathological polymers of Z AAT that form within hepatocytes of individuals with AATD-associated liver disease (14) and so are likely to have a similar conformation. An alternative explanation is that the 2C1 mAb is detecting the Z AAT within the SZ heteropolymer. Both Z and S AAT can form polymers independently (1, 11) and form heteropolymers when incubated together in vitro (29) . The ability to form heteropolymers within cells most likely reflects the ability of each protein to form an unstable intermediate conformer (M*) which acts as nucleus for heteropolymer formation (1) . However, it may result from destabilised Z and S molecules binding from a near-native conformation (31) .
Analysis of the intracellular kinetics demonstrated that copolymerization with Z AAT influenced the intracellular fate of S AAT. Indeed, upon co-expression with Z, there was slower intracellular clearance of S AAT, suggesting that copolymerization with Z decreases the fraction of S destined for degradation (10) . The formation of intracellular heteropolymers did not have a significant effect on secretion of the S mutant. One surprising finding is that Z AAT can also form heteropolymers with wild-type M AAT. This increased intracellular retention of M AAT, but similar to the S variant, had no effect on secretion. M AAT folds rapidly and traffics through the secretory pathway. An interaction between M and Z AAT was not seen when the two proteins were incubated together in vitro (29) . This suggests that heteropolymer formation must occur while the M and Z AAT are folding within the cell, rather than from native conformers of protein. However, we cannot exclude alternative AAT polymerization patterns that have been proposed for Z (1) as well as for rare AAT variants (22, 32) .
It is known that polymerization of Z AAT dramatically changes the architecture of the ER as a result of the formation of IB. This may reduce the mobility of cargo proteins in the ER lumen (24, 30) , as well as their transport in the exocytic pathway. Our data did not reveal a dominant negative effect of Z AAT on secretion of either the normal M or the S variant, in agreement with the concept that plasma levels in MZ and SZ heterozygotes result from independent secretion of the two variants. Indeed, even in the presence of Z aggregates, a large part of the ER network, marked by CRT staining, preserves its architecture and likely its secretory function. Moreover, a previous report showed that, in cells expressing Z AAT, IB maintain capabilities of protein synthesis and vesicular exchange (24) .
Taken together our data show that Z AAT can form heteropolymers with other mutants and with wild-type AAT. Heteropolymer formation delays clearance but does not affect secretion of S or M AAT. Heteropolymer formation will increase the load of polymers within the ER and hence the risk of liver disease, particularly where the liver is exposed to a second 'hit' such as alcohol, fat or viral hepatitis. The formation of heteropolymers helps to explain the presence of liver disease in individuals who are heterozygous for AAT deficiency.
Material and Methods
Reagents and antibodies
Reagents and antibodies are listed in Supplementary Material, Tables S2 and S3, respectively.
Expression vectors
The expression vectors encoding for human M1(Val213) and Z AAT are based on pcDNA3.1/Zeo (þ) (20) . Z HA , Z myc , M HA and M myc were cloned in pcDNA3.1(þ) vector as previously described (23 
SDS-PAGE, non-denaturating PAGE and immunoblot
NP40-soluble or NP40-insoluble cellular fractions, total cell media or IP samples were resolved by 7.5 or 10% SDS-PAGE, as indicated in the legends. For non-denaturing analysis, samples were run on 7.5% native PAGE as previously described (22) . The gels were blotted to PVDF membranes by wet transfer and probed with the indicated primary antibodies, revealed with HRP-conjugated secondary antibodies and detected by ECL Clarity and exposure to Hyperfilm ECL.
CHX treatment
16 h after transfection, HeLa cells were incubated in culture medium supplemented with 50 mg/ml CHX for 8 h at 37 C. Cells were lysed at the indicated time points and the NP40-soluble fractions were analysed by SDS-PAGE followed by immunoblot.
Sandwich ELISA
Quantification of AAT in cell media was performed by sandwich ELISA as previously described (22) using rabbit anti-AAT pAb for capture and HRP-conjugated sheep anti-AAT pAb for detection. AAT concentrations were calculated for each experiment using a standard curve of purified AAT and expressed as percentages of M AAT concentration.
Confocal microscopy and PLA
For immunofluorescence, HeLa cells were grown on glass coverslips, transfected and, 24 h later, fixed and permeabilized as described previously (20) . Cells were then stained with anti-HA, anti-myc, anti-CRT or anti-GM130 antibodies, followed by Alexa-conjugated secondary antibodies and the coverslips were mounted in PBS/Glycerol. Confocal imaging was performed by the LSM510META confocal microscope and Zen2009 software (Zeiss, Italy) at 18 C with 488 and 543 nm excitation wavelengths in multi-track mode. Sub-cellular co-localization analysis was based on Mander's coefficient calculated by ImageJ Plugin JACoP (34).
For PLA (Duolink-Red), cells, transfected on coverslips as above, were co-stained with mouse anti-HA mAb and rabbit anti-myc pAb. Cells were further incubated with the PLA reagents according to the manufacturer's protocol and nuclei stained with DAPI. Cells were imaged by the LSM510META confocal microscope at 405 and 543 nm. PLA signals were quantified using Blobfinder Software (Centre for Image Analysis, Uppsala University, USA).
Statistical analysis
All the statistical analyses were performed by software Prism5 (GraphPad software Inc, San Diego, USA) as detailed in the figure legends.
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